The value of staging laparoscopy in gastric cancer

Authors Nikolaos Machairas, Petros Charalampoudis, Ernesto P. Molmenti, Stylianos Kykalos, Peter Tsaparas, Paraskevas Stamopoulos, Georgios C. Sotiropoulos.


Treatment options for patients with gastric cancer (GC) are based on tumor staging and resectability. Although only surgery provides improved survival, resection is contraindicated and should be avoided in the presence of intra-abdominal disease stage M1 (liver, peritoneal, or nonlocal lymph node metastases). Thus, a detailed and precise evaluation is imperative for optimal treatment. Staging laparoscopy (SL) constitutes a major tool in the accurate diagnosis of several types of cancers, including GC. SL presents several critical advantages: it can diagnose intraabdominal disease; serve as a complement to other imaging studies; allow for biopsies; facilitate intraoperative ultrasound evaluations; allow for sampling of peritoneal fluid for cytological examination; and serve as an option for the administration of intraperitoneal chemotherapy. Although considered and advocated as a very useful asset in the pre-treatment cancer-staging arsenal, the wider application of SL has been long debated. The purpose of our study was to evaluate the contribution of laparoscopy to GC staging.

Keywords Gastric cancer, staging, laparoscopy

Ann Gastroenterol 2017; 30 (3): 287-294

Review Articles